Civilization
Ventures

Essential Innovations

Learn More
The future of healthcare is preventative, personalized, and regenerative. We back inspired founders solving essential problems.

Committed Partners

Starting with a $1M “pilot” seed fund in 2017, Civilization Ventures today manages over $100M in capital and has partnered with 60+ innovative companies.
Learn More

A Fellowship

We train today’s PhDs to become tomorrow’s entrepreneurs with our unique Fellowship program – 30+ strong and growing!
Learn More

Who We Are

learn more

Builders

We help founders succeed through our vast network and team of experienced biopharma executives.

Operators

We have founded and sold companies, so we understand the unique challenges faced by entrepreneurs.

Mentors

“Shahram shared our vision and gave us the tools we needed to build a genome editing pioneer.” - Shakked Halperin, Founder/CEO of Rewrite (acq. by Intellia)

60+ Investments, 9 Exits, 4 Unicorns in 7 Years

2017

CV Fund I

Civilization launches with a $1M pilot fund to back innovators in genomics + diagnostics, digital health and synthetic biology (including gene + cell therapies).

2018

Rocket Pharma listed (NASDAQ: RCKT)

Rocket Pharma lists on Nasdaq, and a unicorn is born. Rocket has multiple first-in-class gene therapies in clinical trials to cure devastating inherited diseases.

2019

Singular Bio acquired by Invitae

Singular Bio is acquired by Invitae to help increase access to accurate genetic screening in early pregnancy.

2020

CV Fund II ($35M)

Civilization raises $35M second fund to lead pre/seed investments just as the world deals with the COVID pandemic and vaccine efforts begin.

2021

Lemonaid Health acquired by 23andme

Lemonaid Health - a pioneer in telemedicine - joins forces with genetic testing leader 23andme in a landmark $400M acquisition.

2022

Rewrite acquired by Intellia

Gene editing pioneer Rewrite - with CV as its founding investor - is acquired by Intellia for $200M in a key move for the industry.

2023

CV Opportunity Fund

Civilization raises its Opportunity Fund to back founders as they scale, bringing our total capital under management to over $100M.

CV Fund I

Rocket Pharma listed (NASDAQ: RCKT)

Singular Bio acquired by Invitae

CV Fund II ($35M)

Lemonaid Health acquired by 23andme

Rewrite acquired by Intellia

CV Opportunity Fund (>$100M total)

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Aspect Biosystems

Lorem ipsum dolor sit amet consectetur inater.

Replace Therapeutics

Lorem ipsum dolor sit amet consectetur inater.

Kernal Bio

Lorem ipsum dolor sit amet consectetur inater.

Foresight Diagnostics

Lorem ipsum dolor sit amet consectetur inater.